

## SUBLINGUAL AND TRANSMUCOSAL BUPRENORPHINE FOR OPIOID USE DISORDER: REVIEW AND UPDATE

This *Advisory* reviews current information on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder. The intended audiences are prescribing physicians, other healthcare professionals, and healthcare policymakers. Topics include new formulations of buprenorphine, the effectiveness and safety of buprenorphine treatment, contraindications and cautions (including medication interactions), informed consent and treatment agreements, treatment monitoring, and indications of diversion and misuse.

Opioid misuse remains a significant problem in the United States. According to the 2014 National Survey on Drug Use and Health (NSDUH), 914,000 people ages 12 or older used heroin in the past year; 586,000 had heroin use disorder.<sup>1</sup> Nonmedical use of prescription pain relievers continues to be more widespread than heroin use—the NSDUH estimates that 4.3 million people currently engage in nonmedical use of pain relievers and that 1.9 million people have a pain reliever use disorder.<sup>1</sup>

Mortality and morbidity are significant concerns. Hospitalizations involving opioid overuse among adults increased more than 150 percent between 1993 and 2012.<sup>2</sup> The National Center for Health Statistics reports that although deaths from opioid analgesics have leveled off in recent years, 16,235 people died of an opioid analgesic-related overdose in 2013. Heroin deaths nearly tripled between 2010 and 2013, increasing to 8,257 deaths in 2013.<sup>3</sup>

Medication-assisted treatment (MAT) is an important part of an effective response to opioid use disorder.<sup>4</sup> MAT, “including opioid treatment programs, combines behavioral therapy and medications to treat substance use disorders.”<sup>5</sup> Products approved by the Food and Drug Administration (FDA) for use in treating opioid use disorder include methadone, buprenorphine (or

### Is MAT “Recovery?”

Recovery status is best defined by factors other than medication status. Neither medication-assisted treatment of opioid addiction nor the cessation of such treatment by itself constitutes recovery. Recovery status instead hinges on broader achievements in health and social functioning—with or without medication support.

—Recovery experts A. Thomas McLellan and William White<sup>6</sup>

buprenorphine with naloxone), and naltrexone.\* These medications have been shown to be effective, safe, and cost-effective treatments when used and monitored properly.<sup>7</sup>

MAT, particularly with opioid agonist medications, has been found to reduce morbidity and mortality, decrease overdose deaths, reduce transmission of infectious disease, increase treatment retention, improve social functioning, and reduce criminal activity.<sup>7</sup> National and international health organizations, such as the American Society of Addiction Medicine (ASAM)<sup>8</sup> and the World Health Organization,<sup>9</sup> consider MAT an evidence-based best practice for treating opioid use disorder. A study<sup>10</sup> involving needle exchange program participants suggests that those who misuse opioids are both aware of and interested in buprenorphine therapy. However, despite governmental and professional endorsement of MAT, and potential patients’ apparent interest in it, there remains a significant gap between the need for and the availability of this treatment.<sup>10,11</sup>

\* More specifically, methadone and buprenorphine (or buprenorphine/naloxone) are approved to treat opioid dependence; extended-release injectable naltrexone is approved for prevention of relapse to opioid use.

## Online DATA 2000 Waiver-Qualifying Training Resource

[www.samhsa.gov/medication-assisted-treatment/training-resources/buprenorphine-physician-training](http://www.samhsa.gov/medication-assisted-treatment/training-resources/buprenorphine-physician-training)

The Drug Addiction Treatment Act of 2000 (DATA 2000) enables qualifying physicians to receive a waiver from the special registration requirements in the Controlled Substances Act in order to prescribe an opioid agonist for the medication-assisted treatment of opioid use disorder. The waiver applies to Schedule III, IV, or V medications specifically approved by FDA for the treatment of opioid use disorder. Buprenorphine-containing products are currently the only pharmacotherapy covered by DATA 2000. To obtain a waiver, a physician must submit to the Substance Abuse and Mental Health Services Administration (SAMHSA) a notice of intent to prescribe buprenorphine. Detailed information on physician waiver qualifications can be found through SAMHSA's Buprenorphine Waiver Management Web page ([www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management](http://www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management)). To qualify, a physician must hold a valid medical license, be registered with the Drug Enforcement Administration, be capable of referring patients to counseling and other services, and meet at least one of the following criteria:<sup>12</sup>

- Hold a subspecialty board certification in addiction medicine or addiction psychiatry
- Have completed not less than 8 hours of approved training
- Have participated as an investigator in one or more clinical trials leading to the approval of a narcotic drug in Schedules III, IV, or V for maintenance or detoxification treatment
- Have experience or training deemed by his or her state medical licensing board or the U.S. Department of Health and Human Services to demonstrate the ability to treat and manage opioid dependence

## Buprenorphine Products

Buprenorphine is available either alone (the mono-product) or in combination with naloxone (the combination product). Naloxone is an opioid antagonist with low bioavailability when taken orally or sublingually; when the combination product is taken as directed, naloxone has little effect on the action and efficacy of buprenorphine.<sup>13</sup> However, if the

combination product is injected, the naloxone produces significant attenuation of buprenorphine's effects and may precipitate acute withdrawal.<sup>14</sup> The combination product is designed to be less subject to diversion and injection misuse than the mono-product. For this reason, the combination product is the preferred formulation for all patients, with the exception of pregnant women<sup>15</sup> and those with a demonstrated allergy to naloxone.

Buprenorphine, both as a mono- and as a combination product, has long been available in sublingual tablet form. Newer formulations include a soluble buprenorphine/naloxone film for sublingual or buccal use. The films dissolve more quickly than tablets, an advantage when monitored dose ingestion is indicated.<sup>16</sup>

Two new formulations (Zubsolv sublingual tablets and Bunavail buccal film) provide higher bioavailability of buprenorphine than other formulations. Higher bioavailability means that more buprenorphine enters the bloodstream, allowing for lower doses. For example, one Bunavail 4.2 mg/0.7 mg buccal film provides buprenorphine exposure equivalent to one Suboxone 8 mg/2 mg sublingual tablet;<sup>17</sup> one Zubsolv 5.7 mg/1.4 mg sublingual tablet provides buprenorphine exposure equivalent to one Suboxone 8 mg/2 mg sublingual tablet.<sup>18</sup>

Exhibit 1 provides a list of available buprenorphine products. As the safety and efficacy of each of these products are considered equivalent, practitioners should use the most cost-effective formulation that is most appropriate for the patient. Medicare Part D and many state Medicaid programs cover buprenorphine products.

## Review: Effectiveness and Safety of Buprenorphine

Research has shown buprenorphine to be an effective pharmacotherapy for treating opioid use disorder. Clinical trials have demonstrated the efficacy of buprenorphine through patient retention and reductions in opioid-positive drug test results. For example, a Cochrane review<sup>19</sup> evaluated the effectiveness of buprenorphine maintenance with various formulations of buprenorphine and buprenorphine/naloxone compared with placebo and with methadone maintenance treatment. The authors examined 31 randomized clinical trials (involving 5,430 participants). They found that, compared with placebo, buprenorphine was effective at retaining patients in treatment at any dose above 2 mg, and was effective at

### Exhibit 1. Buprenorphine Products for Treatment of Opioid Use Disorder

Product Name/Active Ingredient(s)	Route of Administration/Form	Available Strengths	Recommended Once-Daily Maintenance Dose
<b>Bunavail®<sup>17,20</sup></b> <ul style="list-style-type: none"> <li>• Buprenorphine hydrochloride</li> <li>• Naloxone hydrochloride</li> </ul>	Buccal film	2.1 mg/0.3 mg 4.2 mg/0.7 mg 6.3 mg/1 mg	Target: 8.4 mg/1.4 mg Range: 2.1 mg/0.3 mg to 12.6 mg/2.1 mg
<b>Generic combination product<sup>20,21</sup></b> <ul style="list-style-type: none"> <li>• Buprenorphine hydrochloride</li> <li>• Naloxone hydrochloride</li> </ul>	Sublingual tablet	2 mg/0.5 mg 8 mg/2 mg	Target: 16 mg/4 mg Range: 4 mg/1 mg to 24 mg/6 mg*
<b>Generic mono-product<sup>20,22</sup></b> <ul style="list-style-type: none"> <li>• Buprenorphine hydrochloride</li> </ul>	Sublingual tablet	2 mg 8 mg	Target: 16 mg Range: 4 mg to 24 mg*
<b>Suboxone®<sup>20,23</sup></b> <ul style="list-style-type: none"> <li>• Buprenorphine hydrochloride</li> <li>• Naloxone hydrochloride</li> </ul>	Sublingual film	2 mg/0.5 mg 4 mg/1 mg 8 mg/2 mg 12 mg/3 mg	Target: 16 mg/4 mg Range: 4 mg/1 mg to 24 mg/6 mg*
<b>Zubsolv®<sup>18,20</sup></b> <ul style="list-style-type: none"> <li>• Buprenorphine hydrochloride</li> <li>• Naloxone hydrochloride</li> </ul>	Sublingual tablet	1.4 mg/0.36 mg 2.9 mg/0.71 mg 5.7 mg/1.4 mg 8.6 mg/2.1 mg 11.4 mg/2.9 mg	Target: 11.4 mg/2.9 mg Range: 2.9 mg/0.71 mg to 17.2 mg/4.2 mg

\* Dosages higher than 24 mg buprenorphine per day and 24 mg/6 mg buprenorphine/naloxone per day have not been demonstrated to provide a clinical advantage.<sup>22,23</sup>

suppressing illicit opioid use at doses equivalent to 16 mg or greater. However, buprenorphine was not as effective as methadone at retaining patients in treatment.

Maintenance treatment with buprenorphine is more effective than short-term buprenorphine treatment followed by medication tapering. A recent study<sup>24</sup> examined use of buprenorphine to treat patients dependent on prescription opioids. The study compared use of a buprenorphine taper (6 weeks stabilization plus a 3-week taper) with ongoing buprenorphine maintenance and found that maintenance was superior to tapering in both patient retention and rate of relapse to opioid use. Earlier, Weiss et al.<sup>25</sup> found that patients being treated for prescription opioid dependence were most successful at reducing opioid use while receiving buprenorphine (with naloxone) treatment. Even after 12 weeks of medication treatment with concurrent counseling, tapering was associated with very high relapse rates (higher than 90 percent, 8 weeks post-taper).

Studies have also assessed the efficacy of treatment with buprenorphine products in primary care settings and have

found that buprenorphine can be safely and effectively used in these settings.<sup>26,27</sup>

One characteristic of buprenorphine, a partial mu opioid agonist, is that it is safer than full agonists (e.g., methadone) because of its relatively poor bioavailability and its ceiling effect.<sup>15,28</sup> The ceiling effect means that as the buprenorphine dose increases, its effects (including respiratory depression) increase but only to a point. A plateau is reached at moderate doses, meaning the effects no longer increase even as the dose is increased. This ceiling effect also means that buprenorphine carries a lower risk of misuse, dependence, and side effects than full agonists.<sup>15,28</sup> However, there is still some risk of overdose, particularly if the patient concurrently uses another opioid, benzodiazepines, alcohol, sedatives, or certain medications that interact with buprenorphine (see Exhibits 2–4). Overdose prevention education and a prescription for naloxone (in case of overdose) should be considered for all patients considering or receiving buprenorphine; these should be provided again prior to discontinuation of MAT.

## Exhibit 2. Buprenorphine and Buprenorphine/Naloxone Contraindications and Cautions

Contraindication/Caution	Management
<b>Demonstrated allergy/hypersensitivity to buprenorphine (or naloxone)</b>	Do not prescribe. <sup>22</sup>
<b>Compromised respiratory function</b> (e.g., chronic obstructive pulmonary disease, decreased respiratory reserve, hypoxia, hypercapnia [abnormally elevated carbon dioxide levels in the blood], preexisting respiratory depression)	Prescribe with caution; monitor closely. Warn patients about the risk of using benzodiazepines or other depressants while taking buprenorphine. <sup>22</sup>
<b>Hepatic impairment</b> <i>Both buprenorphine and naloxone are extensively metabolized by the liver. Moderate to severe liver impairment results in decreased clearance, increasing overall exposure to both medications, and resulting in higher risk of buprenorphine toxicity and precipitated withdrawal from naloxone. These effects have not been observed in patients with mild hepatic impairment.<sup>22,29</sup></i>	<b>Mild</b> impairment (Child-Pugh score of 5–6): <sup>30</sup> No dose adjustment needed. <b>Moderate</b> impairment (Child-Pugh score of 7–9): <sup>30</sup> Combination products are not recommended for induction with patients with moderate hepatic impairment as they may precipitate withdrawal.* However, combination products may be used with caution for maintenance treatment in patients with moderate hepatic impairment who have been inducted with a mono-product; <sup>23,29</sup> patients should be carefully monitored for signs and symptoms of buprenorphine toxicity or overdose. <sup>22</sup> Also consider the possibility of naloxone interfering with buprenorphine’s efficacy. <sup>23,29</sup> <b>Severe</b> impairment (Child-Pugh score of 10–15): <sup>30</sup> Do not use the combination product. <sup>29</sup> With a mono-product, consider reducing the starting and titration doses by half compared with patients with normal liver function; monitor for signs and symptoms of toxicity or overdose caused by increased levels of buprenorphine. <sup>22</sup>

\* Moderate to severe hepatic impairment results in reduced clearance of naloxone much greater than clearance of buprenorphine. Nasser et al.<sup>29</sup> found that moderate hepatic impairment led to 2 to 3 times the exposure (compared with subjects with no or mild impairment) for both naloxone and buprenorphine. In subjects with severe hepatic impairment, buprenorphine exposure was also 2 to 3 times higher; however, naloxone exposure increased more than tenfold.

Exhibit 2 provides contraindications and cautions for use of buprenorphine.

Patients dependent on opioids frequently have co-occurring medical conditions. Rates of HIV infection and hepatitis C virus (HCV) infection are particularly high in people who inject drugs. There appear to be fewer potential interactions between buprenorphine and antiretrovirals (ARVs) than between methadone and ARVs. One explanation is that because buprenorphine is absorbed sublingually (or buccally in newer formulations),

it is less competitive with ARVs for absorption in the gastrointestinal tract.<sup>31</sup>

There appear to be no significant interactions between buprenorphine and most HCV medications. In particular, most direct-acting antivirals approved for the treatment of HCV do not have clinically significant interactions with buprenorphine.<sup>32</sup> Exhibit 3 lists potential interactions between buprenorphine and HIV medications, specifically ARVs. Exhibit 4 lists potential interactions between buprenorphine and medications in several drug classes.

Patients should be closely monitored for cognitive effects and sedation when therapies are initiated or discontinued or dosage is changed. For the most current product-specific information, review the product label (Section 7, Drug Interactions) through [Drugs@FDA](mailto:Drugs@FDA)—[www.accessdata.fda.gov/scripts/cder/drugsatfda](http://www.accessdata.fda.gov/scripts/cder/drugsatfda).

### Exhibit 3. Potential Interactions Between Buprenorphine and HIV Medications

Medication	Type	Potential Interaction
Atazanavir	Protease inhibitor (PI)	Increased buprenorphine concentrations. Some patients may experience cognitive impairment <sup>22,33</sup> or oversedation. <sup>33,34</sup> Slower titration or dose reduction of buprenorphine may be warranted. <sup>22,34</sup>
Darunavir-ritonavir	PI	Some pharmacokinetic (PK) effect; dose adjustments unlikely to be needed but clinical monitoring is recommended. <sup>35</sup>
Delavirdine	Nonnucleoside reverse transcriptase inhibitor (NNRTI)	Increased buprenorphine concentrations, but no clinically significant effect. Dose adjustments unlikely to be needed. However, use with caution, as long-term effects (more than 7 days) are unknown. <sup>34,36</sup>
Efavirenz	NNRTI	Some PK effect; dose adjustments unlikely to be needed. <sup>36</sup>
Elvitegravir (with cobicistat)	Integrase inhibitor	Some PK effect; no dose adjustments needed. <sup>37</sup>
Nevirapine	NNRTI	Some PK effect; no dose adjustments needed. <sup>38</sup>
Ritonavir	PI	Some PK effect; no dose adjustments needed. <sup>39</sup>
Tipranavir	PI	Some PK effect; no dose adjustments needed. <sup>40</sup>

Bruce et al.<sup>34</sup> note some caveats to relying on the current research regarding interactions between buprenorphine and other medications:

- Many studies have small numbers of patients and may not be generalizable to all populations.
- Studies typically exclude patients with many of the disorders that people with HIV, HCV, or both commonly experience (e.g., hepatic and renal impairments).
- Most studies focus on single drug–drug interactions; however, a patient is frequently taking several medications concurrently, the combination of which may not have been studied.
- The need for and level of dose adjustments may vary widely between patients.
- The practitioner must remain alert to the possibility of a medication interaction even when existing data do not support such an interaction.
- When an interaction is likely (e.g., with atazanavir, central nervous system depressants, CYP3A4 inhibitors), the patient should be clinically monitored daily; practitioners should keep in mind that the *timing* of symptom development is variable and depends on a variety of factors.

### Buprenorphine Induction and Stabilization/Maintenance

“The goal of induction and stabilization is to find the lowest dose of buprenorphine at which the patient discontinues or markedly reduces the use of other opioids without experiencing withdrawal symptoms, significant side effects, or uncontrollable craving for the [opioid] of abuse.”<sup>41</sup>

Induction strategies vary somewhat depending on individual patient variables and the type of opioid a patient is using. A discussion of models of buprenorphine induction is at [www.pcsmat.org/wp-content/uploads/2015/02/Buprenorphine-Induction-Online-Module.pdf](http://www.pcsmat.org/wp-content/uploads/2015/02/Buprenorphine-Induction-Online-Module.pdf).

Following treatment induction and stabilization is the maintenance phase. The maintenance dose of Suboxone sublingual film is generally in the range of 4 mg/1 mg buprenorphine/naloxone to 24 mg/6 mg buprenorphine/naloxone per day, with a target of 16 mg/4 mg as a single daily dose<sup>23</sup> (see Exhibit 1 for the recommended maintenance target dosages and ranges for other formulations). The optimal maintenance dose of

## Exhibit 4. Potential Interactions Between Buprenorphine and Other Drug Classes

Drug Class	Potential Interaction
<b>Benzodiazepines</b>	Some reports of coma and death associated with misuse of the combination of buprenorphine (particularly via injection) and benzodiazepines. <sup>22,42</sup> Decreased ceiling effects on buprenorphine-induced respiratory depression, making the respiratory effects similar to those of full mu opioid agonists. <sup>42,43</sup> Dose reduction of the benzodiazepine, of buprenorphine, or both may be necessary. Patients should be warned to use these medications only as directed. <sup>22</sup>
<b>Other central nervous system depressants</b> (e.g., sedatives, hypnotics, general anesthetics, tranquilizers, other opioids, alcohol)	Increased risk of respiratory depression, profound sedation, hypotension, coma, and death. <sup>42</sup>
<b>CYP3A4 inducers</b> (e.g., phenobarbital, carbamazepine, phenytoin, rifampicin)	May cause increased clearance of buprenorphine, which could lead to decreased plasma concentrations, lack of efficacy, or possibly abstinence syndrome. <sup>22,42</sup>
<b>CYP3A4 inhibitors</b> (e.g., azole antifungals such as ketoconazole; macrolide antibiotics such as erythromycin; HIV protease inhibitors; antidepressants such as fluoxetine, fluvoxamine, amitriptyline)	May cause decreased clearance of buprenorphine, leading to increased buprenorphine plasma concentrations and resulting in increased or prolonged opioid effects. Patients should be monitored for respiratory depression and sedation. <sup>42</sup> Dose reduction of either medication may be necessary. <sup>22</sup>
<b>Nonbenzodiazepine muscle relaxants</b> (e.g., carisoprodol, cyclobenzaprine)	May cause an increased degree of respiratory depression. <sup>42</sup>
<b>Anticholinergics</b> (e.g., inhaler medications such as ipratropium bromide, oxitropium bromide, tiotropium; medications used to treat gastrointestinal and urinary tract disorders)	Increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. <sup>42</sup>
<b>Psychostimulants:</b> cocaine	May increase metabolism and diminish plasma concentrations of buprenorphine. <sup>44</sup>

buprenorphine products will vary from patient to patient. Doses should be incrementally adjusted to a level that holds the patient in treatment and suppresses opioid withdrawal effects. Dosages higher than 24 mg/6 mg daily of buprenorphine/naloxone have not been demonstrated to provide a clinical advantage.<sup>23</sup>

### Informed Consent and Treatment Agreements

Informed consent and treatment agreements can clarify expectations of both practitioner and patient and provide a structure for effective monitoring.

### Informed Consent

Practitioners need to discuss the risks and benefits of the treatments available (including other MAT and non-MAT options) for opioid use disorder and should also explain:<sup>41</sup>

- The difference between addiction and physical dependence and why MAT is not simply “switching one addiction for another.”
- The patient’s risk of relapse with and without MAT.
- The estimated duration of treatment with buprenorphine.
- Reasonable expectations for treatment results.
- The importance of counseling and peer support.

A written informed consent should be reviewed and signed by both the practitioner and the patient.

## Treatment Agreements

Treatment agreements should also be written and signed, and updated periodically as treatment progresses. Typical provisions of treatment agreements include:<sup>41</sup>

- Acknowledgment by the patient of the potential benefits and risks of treatment and the goals of treatment.
- Identification of one physician and one pharmacy to provide the patient's opioid prescriptions (for MAT or for other conditions).
- Authorization for the physician and staff to communicate with other named providers of care and, as needed, with significant others.<sup>†</sup>
- Agreement to participate in other treatments or consultations, including counseling, as directed.
- Acknowledgment that the physician will be using the state's prescription drug monitoring program (PDMP; see Monitoring Strategies section, below).
- Agreement to avoid all illicit use of substances.
- Agreement to undergo toxicology screens and pill/film counts upon request.
- Procedures to obtain prescriptions and refills, including exclusion of early refills.
- Expected frequency of office visits.

Patients should be warned of the significant risk all forms of buprenorphine pose to children. Even very brief exposure to buprenorphine formulations can lead to sedation, respiratory depression, cerebral anoxia, and death.<sup>45</sup> Because buprenorphine is absorbed through the lining of the mouth, a child does not need to swallow or chew the medication to have significant exposure, even if the medication is quickly taken out of the child's mouth. A child exposed to buprenorphine in any way, even for a few seconds, requires immediate medical attention and hospital observation for 24 hours.<sup>45</sup> Practitioners should include child-safety recommendations in treatment agreements, such as:<sup>45</sup>

- Keep medications in a location inaccessible to children (e.g., a locked or otherwise secure cabinet).
- Never store buprenorphine in anything other than a child-resistant container.
- If a child *is* exposed, or is thought to have been exposed, to buprenorphine, call 911 immediately.

<sup>†</sup> Communication authorizations must comply with federal law and regulations (Confidentiality of Alcohol and Drug Abuse Patient Records, 42 CFR Part 2).

- Remember that sharing your medication with others could put someone else's household members at risk.

## Behavioral Treatment

Concurrent behavioral treatment is a critical element of MAT. The ASAM National Practice Guideline recommends that prescribers offer patients behavioral treatment early in their buprenorphine treatment.<sup>8</sup> The guideline recommends that behavioral treatment should include, at minimum:<sup>8</sup>

- Assessment of psychosocial needs.
- Supportive individual or group counseling (or both).
- Linkages to existing family support systems.
- Referrals to community-based services.

ASAM notes that models of behavioral treatment that appear to be effective with patients being treated with buprenorphine are:<sup>8</sup>

- Cognitive-behavioral therapies.
- Contingency management.
- Relapse prevention.
- Motivational interviewing.

Mutual-help programs may also benefit patients but are not a substitute for behavioral therapy.

Research shows that when treating SUDs [substance use disorders], a combination of medication and behavioral therapies is the most effective. Behavioral therapies help patients engage in the treatment process, modify their attitudes and behaviors related to drug and alcohol abuse, and increase healthy life skills. These treatments can also enhance the effectiveness of medications and help people stay in treatment longer.<sup>46</sup>

# ADVISORY

Information about incorporating behavioral treatment can be found at:

[www.pcssmat.org/new-pcss-mat-module-posted-developing-a-behavioral-treatment-protocol-in-conjunction-with-mat](http://www.pcssmat.org/new-pcss-mat-module-posted-developing-a-behavioral-treatment-protocol-in-conjunction-with-mat)

[www.pcssmat.org/new-online-module-counseling-mat-better-outcomes-with-integrated-care](http://www.pcssmat.org/new-online-module-counseling-mat-better-outcomes-with-integrated-care)

## Monitoring of Adherence and Response to Treatment

Effective monitoring of adherence and response to treatment can increase the likelihood of positive clinical outcomes and reduce the possibility of diversion.

### Monitoring Strategies

Monitoring medication adherence in office-based settings should include unannounced urine toxicology screening, pill/film counts, and observed ingestion.<sup>47</sup> State PDMPs should also be used.

#### Urine toxicology

Urine testing can be used to determine whether the patient is taking the prescribed buprenorphine and to test for illicit substance use. Point-of-service dipstick tests and laboratory testing may both be useful. The Providers' Clinical Support System for Medication Assisted Treatment suggests these strategies to minimize patients' ability to tamper with urine samples:<sup>47</sup>

- Don't allow patients to take purses, backpacks, and so on into the bathroom.
- Turn off running water and color the toilet water to eliminate possible dilution.
- Monitor the bathroom door so that only the patient can go in.
- Test the temperature, specific gravity, and creatinine of the urine immediately after it has been voided.

It is important to remember that urine toxicology is only a tool and should not be relied upon exclusively for clinical decision making.

#### Pill/film counts

The practitioner should have the patient bring his or her medication container to each appointment to show that the medication is being taken as directed. Unannounced inventories can help ensure that medication is not being diverted.

#### Observed ingestion

Observed ingestion (having the patient take the medication in front of the practitioner or a trained monitor) at the beginning of buprenorphine therapy can help the practitioner ensure that the patient knows how to take the medication. Later in therapy, observing ingestion periodically can help patients adhere to therapy.

See SAMHSA's Technical Assistance Publication (TAP) 32, *Clinical Drug Testing in Primary Care*, for additional information about drug testing.

#### Prescription drug monitoring programs

PDMPs are state-operated electronic databases that collect data on controlled substances (and, in some cases, over-the-counter medications) dispensed in the state. PDMPs help physicians monitor whether patients are obtaining the prescribed medication, obtaining prescriptions for controlled substances from other prescribers, or refilling prescriptions early. Where available, prescribers should register with and check the PDMP for each patient before buprenorphine induction and prior to writing prescriptions. So that there is clear communication and transparency, patients should be informed up front that the PDMP will be accessed to monitor their controlled prescription drug use. PDMP information can also help practitioners educate patients about the risk of overdose and potential drug-drug interactions, particularly related to benzodiazepines and other sedative-hypnotics.

The PDMP Training and Technical Assistance Center Web site provides current information about PDMPs at [www.pdmpassist.org](http://www.pdmpassist.org).

## Responding to Patient Behaviors

Practitioners should verbally acknowledge and reinforce a patient's adherence to treatment, reduction of illicit drug use, and positive life changes. Practitioners may also concretely reinforce progress by reducing the frequency of office visits and/or increasing the patient's responsibility for his or her medication.<sup>41</sup> Some patients will continue to illicitly use opioids and/or other substances or relapse to opioid use after a period of abstinence. Other patients may have trouble adhering to the treatment plan (e.g., not taking buprenorphine as directed, missing appointments). Diversion or misuse of buprenorphine may also occur. Signs and behaviors suggestive of diversion and misuse of buprenorphine products include:<sup>47</sup>

- Unsupported claims of intolerance or allergy to naloxone to obtain the mono-product, which is more subject to misuse.
- Early requests for refills for unsubstantiated reasons (e.g., prescription was "lost" or "stolen").
- Difficulty keeping appointments or providing payment.
- A sudden request for a dose increase by a previously stabilized patient.
- Positive toxicology screens for illicit substance use or negative toxicology screens for buprenorphine.
- Ongoing close ties to individuals (e.g., spouse, partner, significant others, friends) who sell opioids or have opioid use disorder but are not in treatment.

Relapse or continued substance use are not reasons for automatically discontinuing MAT.<sup>41</sup> Instead, either situation should prompt discussion with the patient and evaluation of the treatment plan. If the situation is handled well, a stronger patient–physician alliance can be formed. Changes to treatment should be made on an individual basis and could include any combination of the following: adjusting the patient's buprenorphine dosage, increasing the frequency of office visits, requiring supervised administration, intensifying counseling, or encouraging the patient to engage in more intensive peer support programs.<sup>41,47</sup> Some patients may require more structured treatment, such as that offered in a residential program or an opioid treatment program.<sup>41,47</sup> See the Resources section of this publication for treatment locators.

## Duration and Discontinuation of Treatment

The optimal duration of office-based buprenorphine treatment remains unclear. A decision to discontinue buprenorphine therapy should be made based on clinical judgment and upon mutual agreement by the practitioner and patient. ASAM suggests that certain factors may be associated with successful discontinuation of buprenorphine treatment:<sup>8</sup>

- Employment, engagement in mutual-help programs, or involvement in other meaningful activities
- Sustained abstinence from opioids and other substances during treatment
- Positive changes in the psychosocial environment
- Evidence of additional psychosocial supports
- Persistent engagement in treatment for ongoing monitoring past the point of medication discontinuation

Discontinuation of buprenorphine therapy requires a tapering regimen. ASAM recommends a slow taper (usually over several months) with close monitoring. A patient who relapses to illicit use of opioids should resume MAT.<sup>8</sup>

## Resources

### Relevant Publications From SAMHSA

(see back page for electronic access and ordering information)

Technical Assistance Publication (TAP) 30:  
*Buprenorphine: A Guide for Nurses*

TAP 32: *Clinical Drug Testing in Primary Care*

Treatment Improvement Protocol (TIP) 40: *Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction*

TIP 43: *Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs*

### Other Resources

**Behavioral Health Treatment Services Locator**  
<http://findtreatment.samhsa.gov>

**Buprenorphine Treatment Physician Locator**  
[www.samhsa.gov/medication-assisted-treatment/physician-program-data/treatment-physician-locator](http://www.samhsa.gov/medication-assisted-treatment/physician-program-data/treatment-physician-locator)

# ADVISORY

## Medication-Assisted Treatment Web Site

[www.samhsa.gov/medication-assisted-treatment](http://www.samhsa.gov/medication-assisted-treatment)

## Opioid Treatment Program Directory

<http://dpt2.samhsa.gov/treatment/directory.aspx>

## National Alliance for Model State Drug Laws

[www.namsdl.org/prescription-monitoring-programs.cfm](http://www.namsdl.org/prescription-monitoring-programs.cfm)

## Poison Help Line

1-800-222-1222 (24 hours a day, 7 days a week)

[www.aapcc.org](http://www.aapcc.org)

## Prescription Drug Monitoring Program Center of Excellence

[www.pdmpexcellence.org](http://www.pdmpexcellence.org)

## Prescription Drug Monitoring Program Training and Technical Assistance Center

[www.pdmpassist.org](http://www.pdmpassist.org)

## Providers' Clinical Support System for Medication Assisted Treatment

[www.pcssmat.org](http://www.pcssmat.org)

## Notes

- <sup>1</sup> Substance Abuse and Mental Health Services Administration. (2015). *Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health*. NSDUH Series H-50, HHS Publication No. (SMA) 15-4927. Rockville, MD: Substance Abuse and Mental Health Services Administration.
- <sup>2</sup> Owens, P. L., Barrett, M. L., Weiss, A. J., Washington, R. E., & Kronick, R. (2014). *Hospital inpatient utilization related to opioid overuse among adults, 1993-2012*. HCUP Statistical Brief #177. Rockville, MD: Agency for Healthcare Research and Quality.
- <sup>3</sup> Hedegaard, H., Chen, L.-H., & Warner, M. (2015, March). *Drug-poisoning deaths involving heroin: United States, 2000–2013*. NCHS Data Brief, No. 190. Hyattsville, MD: National Center for Health Statistics, Centers for Disease Control and Prevention. Retrieved January 20, 2016, from [www.cdc.gov/nchs/data/databriefs/db190.pdf](http://www.cdc.gov/nchs/data/databriefs/db190.pdf)
- <sup>4</sup> National Institute on Drug Abuse. (2012). *Principles of drug addiction treatment: A research-based guide* (3rd ed.). NIH Publication No. 12-4180. Bethesda, MD: Author.
- <sup>5</sup> Substance Abuse and Mental Health Services Administration. (n.d.). *Medication-assisted treatment* [Web page]. Retrieved January 22, 2016, from [www.samhsa.gov/medication-assisted-treatment](http://www.samhsa.gov/medication-assisted-treatment)
- <sup>6</sup> McLellan, A. T., & White, W. (2012). *Opioid maintenance and recovery-oriented systems of care: It is time to integrate* (p. 2). London, England: National Treatment Agency for Substance Misuse.

- <sup>7</sup> Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014). Medication-assisted therapies—Tackling the opioid-overdose epidemic. *New England Journal of Medicine*, 370(22), 2063–2066.
- <sup>8</sup> American Society of Addiction Medicine. (2015). *National practice guideline for the use of medications in the treatment of addiction involving opioid use*. Retrieved January 20, 2016, from [www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/national-practice-guideline.pdf?sfvrsn=22](http://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/national-practice-guideline.pdf?sfvrsn=22)
- <sup>9</sup> World Health Organization. (2009). *Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence*. Geneva, Switzerland: Author.
- <sup>10</sup> Fox, A. D., Shah, P. A., Sohler, N. L., Lopez, C. M., Starrels, J. L., & Cunningham, C. O. (2014). I heard about it from a friend: Assessing interest in buprenorphine treatment. *Substance Abuse*, 35(1), 74–79.
- <sup>11</sup> Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015). National and state treatment need and capacity for opioid agonist medication-assisted treatment. *American Journal of Public Health*. Advance online publication. doi:10.2105/AJPH.2015.302664
- <sup>12</sup> Substance Abuse and Mental Health Services Administration. (n.d.). *Buprenorphine waiver management* [Web page]. Retrieved January 20, 2016, from [www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management](http://www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management)
- <sup>13</sup> Chiang, C. N., & Hawks, R. L. (2003). Pharmacokinetics of the combination tablet of buprenorphine and naloxone. *Drug and Alcohol Dependence*, 70(Suppl. 2), S39–S47.
- <sup>14</sup> Yokell, M. A., Zaller, N. D., Green, T. C., & Rich, J. D. (2011). Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. *Current Drug Abuse Review*, 4(1), 28–41.
- <sup>15</sup> Center for Substance Abuse Treatment. (2004). *Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction*. Treatment Improvement Protocol (TIP) Series 40. HHS Publication No. (SMA) 07-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration.
- <sup>16</sup> Strain, E. C., Harrison, J. A., & Bigelow, G. E. (2011). Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. *Clinical Pharmacology and Therapeutics*, 89(3), 443–449.
- <sup>17</sup> BioDelivery Sciences International. (2014). *Bunavail (buprenorphine and naloxone) buccal film: Full prescribing information*. Retrieved January 22, 2016, from [www.bdsi.com/siteres.aspx?resid=5a738443-a797-41cd-a39a-a8deb2a4a585](http://www.bdsi.com/siteres.aspx?resid=5a738443-a797-41cd-a39a-a8deb2a4a585)
- <sup>18</sup> Orexo US. (2015). *Zubsolv (buprenorphine and naloxone) sublingual tablets: Full prescribing information*. Retrieved January 22, 2016, from [www.zubsolv.com/wp-content/uploads/2015/01/ZubsolvFullPrescribingInformation.pdf](http://www.zubsolv.com/wp-content/uploads/2015/01/ZubsolvFullPrescribingInformation.pdf)
- <sup>19</sup> Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database of Systematic Reviews*, 2014(2), i–84. doi:10.1002/14651858.CD002207.pub4

- <sup>20</sup> Food and Drug Administration. (n.d.). Drugs@FDA: FDA approved drug products. Retrieved January 22, 2016, through [www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm](http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm)
- <sup>21</sup> Roxane Laboratories. (2015). *Buprenorphine and naloxone sublingual tablets: Full prescribing information*. Retrieved January 22, 2016, from <http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=713db2c6-0544-4633-b874-cf93db89>
- <sup>22</sup> Roxane Laboratories. (2015). *Buprenorphine HCl sublingual tablets: Full prescribing information*. Retrieved January 22, 2016, from <http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bf8b35a-b769-465c-a2f8-099868dfcd2f>
- <sup>23</sup> Indivior. (2015). *Suboxone (buprenorphine and naloxone) sublingual film: Full prescribing information*. Retrieved January 22, 2016, from [www.suboxone.com/content/pdfs/prescribing-information.pdf](http://www.suboxone.com/content/pdfs/prescribing-information.pdf)
- <sup>24</sup> Fiellin, D. A., Schottenfeld, R. S., Cutter, C. J., Moore, B. A., Barry, D. T., & O'Connor, P. G. (2014). Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial. *JAMA Internal Medicine*, 174(12), 1947–1954.
- <sup>25</sup> Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., et al. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. *Archives of General Psychiatry*, 68(12), 1238–1246.
- <sup>26</sup> Finch, J. W., Kamien, J. B., & Amass, L. (2007). Two-year experience with buprenorphine-naloxone (Suboxone) for maintenance treatment of opioid dependence within a private practice setting. *Journal of Addiction Medicine*, 1(2), 104–110.
- <sup>27</sup> Mintzer, I. L., Eisenberg, M., Terra, M., MacVane, C., Himmelstein, D. U., & Woolhandler, S. (2007). Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. *Annals of Family Medicine*, 5(2), 146–150.
- <sup>28</sup> Substance Abuse and Mental Health Services Administration. (n.d.). *Buprenorphine* [Web page]. Retrieved January 20, 2016, from [www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine](http://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine)
- <sup>29</sup> Nasser, A. F., Heidbreder, C., Liu, Y., & Fudala, P. J. (2015). Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (Child-Pugh classes A, B, and C), in hepatitis C virus-seropositive subjects, and in healthy volunteers. *Clinical Pharmacokinetics*. Advance online publication. doi:10.1007/s40262-015-0238-6
- <sup>30</sup> Durand, F., & Valla, D. (2008). *Assessment of prognosis of cirrhosis. Seminars in Liver Disease*, 28(1), 110–122.
- <sup>31</sup> Gruber, V. A., & McCance-Katz, E. F. (2010). Methadone, buprenorphine, and street drug interactions with antiretroviral medications. *Current HIV/AIDS Reports*, 7(3), 152–160.
- <sup>32</sup> Meemken, L., Hanhoff, N., Tseng, A., Christensen, S., & Gillissen, A. (2015). Drug-drug interactions with antiviral agents in people who inject drugs requiring substitution therapy. *Annals of Pharmacotherapy*, 49(7), 796–807.
- <sup>33</sup> McCance-Katz, E. F., Moody, D. E., Morse, G. D., Ma, Q., DiFrancesco, R., Friedland, G., et al. (2007). Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. *Drug and Alcohol Dependence*, 91(2–3), 269–278.
- <sup>34</sup> Bruce, R. D., Moody, D. E., Altice, F. L., Gourevitch, M. N., & Friedland, G. H. (2013). A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: Implications and management for clinical practice. *Expert Review of Clinical Pharmacology*, 6(3), 249–269.
- <sup>35</sup> Gruber, V. A., Rainey, P. M., Moody, D. E., Morse, G. D., Ma, Q., Prathikanti, S., et al. (2012). Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir. *Clinical Infectious Diseases*, 54(3), 414–423.
- <sup>36</sup> McCance-Katz, E. F., Moody, D. E., Morse, G. D., Friedland, G., Pade, P., Baker, J., et al. (2006). Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. *Clinical Infectious Diseases*, 43(Suppl. 4), S224–S234.
- <sup>37</sup> Bruce, R. D., Winkle, P., Custodio, J., Yin, X., Rhee, M., Andrews, J., et al. (2012, September). *Pharmacokinetics of cobicistat-boosted elvitegravir administered in combination with methadone or buprenorphine/naloxone*. Paper presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. Abstract retrieved January 20, 2016, from [www.natap.org/2012/ICAAC/ICAAC\\_40.htm](http://www.natap.org/2012/ICAAC/ICAAC_40.htm)
- <sup>38</sup> McCance-Katz, E. F., Moody, D. E., Morse, G. D., Ma, Q., & Rainey, P. M. (2010). Lack of clinically significant drug interactions between nevirapine and buprenorphine. *American Journal on Addictions/American Academy of Psychiatrists in Alcoholism and Addictions*, 19(1), 30–37.
- <sup>39</sup> McCance-Katz, E. F., Moody, D. E., Smith, P. F., Morse, G. D., Friedland, G., Pade, P., et al. (2006). Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. *Clinical Infectious Diseases*, 43(Suppl. 4), S235–S246.
- <sup>40</sup> Bruce, R. D., Altice, F. L., Moody, D. E., Lin, S. N., Fang, W. B., Sabo, J. P., et al. (2009). Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. *Drug and Alcohol Dependence*, 105(3), 234–239.
- <sup>41</sup> Federation of State Medical Boards. (2013). *Model policy on DATA 2000 and treatment of opioid addiction in the medical office*. Retrieved January 20, 2016, from [www.fsmb.org/Media/Default/PDF/FSMB/Advocacy/2013\\_model\\_policy\\_treatment\\_opioid\\_addiction.pdf](http://www.fsmb.org/Media/Default/PDF/FSMB/Advocacy/2013_model_policy_treatment_opioid_addiction.pdf)
- <sup>42</sup> PDR Network. (2014). *Physicians' desk reference* (69th ed.). Montvale, NJ: Author.
- <sup>43</sup> Lee, S. C., Klein-Schwartz, W., Doyon, S., & Welsh, C. (2014). Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone. *Drug and Alcohol Dependence*, 138, 118–123.

# ADVISORY

<sup>44</sup> McCance-Katz, E. F., Sullivan, L. E., & Nallani, S. (2010). Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. *American Journal on Addictions, 19*(1), 4–16.

<sup>45</sup> Boyer, E. W., McCance-Katz, E. F., & Marcus, S. (2010). Methadone and buprenorphine toxicity in children. *American Journal on Addictions, 19*(1), 89–95.

<sup>46</sup> Mann, C., Frieden, T., Hyde, P. S., Volkow, N. D., & Koob, G. F. (2014, July 11). *Medication assisted treatment for substance use disorders* (p. 5). Informational Bulletin. Retrieved January 20, 2016, from [www.medicaid.gov/Federal-Policy-Guidance/downloads/CIB-07-11-2014.pdf](http://www.medicaid.gov/Federal-Policy-Guidance/downloads/CIB-07-11-2014.pdf)

<sup>47</sup> Martin, J. (2014). *PCSS Guidance: Adherence, diversion and misuse of sublingual buprenorphine*. Retrieved January 20, 2016, from [www.pcsmat.org/wp-content/uploads/2014/02/PCSS-MATGuidanceAdherence-diversion-bup.Martin.pdf](http://www.pcsmat.org/wp-content/uploads/2014/02/PCSS-MATGuidanceAdherence-diversion-bup.Martin.pdf)

## *SAMHSA Advisory*

This *Advisory* was written and produced under contract numbers 270-09-0307 and 270-14-0445 by the Knowledge Application Program (KAP), a Joint Venture of JBS International, Inc., and The CDM Group, Inc., for the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS). Christina Currier and Suzanne Wise served as the Contracting Officer's Representatives, and Candi Byrne served as KAP Project Coordinator.

**Disclaimer:** The views, opinions, and content of this publication are those of the authors and do not necessarily reflect the views, opinions, or policies of SAMHSA or HHS.

**Public Domain Notice:** All materials appearing in this document except those taken from copyrighted sources are in the public domain and may be reproduced or copied without permission from SAMHSA or the authors. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, HHS.

**Electronic Access and Copies of Publication:** This publication may be ordered or downloaded from SAMHSA's Publications Ordering Web page at <http://store.samhsa.gov>. Or, please call SAMHSA at 1-877-SAMHSA-7 (1-877-726-4727) (English and Español).

**Recommended Citation:** Substance Abuse and Mental Health Services Administration. (2016). Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update. *Advisory*, Volume 15, Issue 1.

**Originating Office:** Quality Improvement and Workforce Development Branch, Division of Services Improvement, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857.

